mardi 8 septembre 2015

Onco Actu du 8 septembre 2015

1. Biologie

Science Snaps: prioritising the gene faults behind bowel cancer [Cancer Research UK]

3.1 Tabac

Study: anti-smoking drug Champix does not raise risk of suicide or depression [The Telegraph]

4.10 Dép., diag. & prono. - Poumon

Lung Screening May Not Push Smokers to Quit [NY Times]

5.12 Immunothérapies

Follow-up Data from Two Pivotal Opdivo (nivolumab) Trials Demonstrates Sustained Survival Results in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer [BMS]

New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer [BMS]

Bristol pairs Yervoy safely with Opdivo vs lung cancer [Reuters]

5.2.1 Pharma - Partenariats

AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester [AstraZeneca]

5.2.3 Pharma - économie

Peter Thiel Backs Biotech “Unicorn” Fighting Cancer Stem Cells [MIT Technology Review]

5.4 Traitements - Economie

NICE recommends pembrolizumab for advanced skin cancer [NICE]

UK backs use of Merck cancer immunotherapy after price discount [Reuters]

Companies struggle to get new medicines adopted across Europe [Reuters]

5.6 ESMO

Genentech to Present Data from 15 Medicines Across Its Portfolio of Cancer Immunotherapy and Targeted Medicines During the 2015 European Cancer Congress [Genentech]

6. Lutte contre les cancers

New data show that more than 50% of patients and carers struggled to cope with challenges of living with lung cancer [Boehringer Ingelheim]

Gynaecological cancer: 'women are literally dying of embarrassment' [The Guardian]

6.11 Patients

How long do I have? Story of a myeloma patient [Cancer World]